10-K: Tilray Brands Reports Significant Net Loss Amid Impairments

Tilray Brands, Inc. reported a substantial net loss of $2.18 billion for fiscal year 2025, primarily driven by non-cash impairment charges totaling over $2 billion on intangible assets and goodwill, despite revenue growth in its beverage, distribution, and wellness segments.

Summary

• Net loss for the fiscal year ended May 31, 2025, was $2.18 billion, an 881% increase from the prior fiscal year's $222.4 million loss.
• Total net revenue increased by 4% to $821.3 million for fiscal year 2025, up from $788.9 million in fiscal year 2024.
• Gross profit rose by 8% to $240.6 million in fiscal year 2025, compared to $223.4 million in fiscal year 2024.
• Operating expenses significantly increased by 534% to $2.52 billion, primarily due to non-cash impairment charges.
• Non-cash impairment charges of intangible assets and goodwill totaled $2.096 billion in fiscal year 2025.
• Adjusted EBITDA decreased by 9% to $55.0 million in fiscal year 2025 from $60.5 million in fiscal year 2024.
• Cash and marketable securities stood at $256.4 million as of May 31, 2025, a slight decrease from $260.5 million in the prior year.
• Working capital increased to $408.3 million as of May 31, 2025, from $378.5 million in the prior year.
• Beverage net revenue grew by 19% to $240.6 million, driven by new HD-D9 products and Craft Acquisition II, partially offset by SKU rationalization under Project 420.
• Cannabis net revenue decreased by 9% to $249.0 million, primarily due to a strategic shift to higher-margin international markets and a focus on preserving gross margin in Canada.
• Distribution net revenue increased by 5% to $271.2 million, driven by a change in product mix.
• Wellness net revenue increased by 9% to $60.5 million, attributed to product range expansion and organic growth in hemp food business.
• The company completed Craft Acquisition II on September 1, 2024, acquiring four craft beer brands and breweries from Molson Coors Beverage Company for $23.0 million in cash.
• Project 420, a synergy optimization plan, increased its target by $8 million to $33 million, with $24.1 million in savings achieved to date, expected to complete in Q3 fiscal 2026.
• The company issued 135,938,741 shares under its At-the-Market (ATM) program, generating $161.2 million in net proceeds.
• The company exchanged $67.5 million of its 5.20% Convertible Senior Notes due June 1, 2027 (TLRY 27 Notes) for 71,755,054 common shares and $9.3 million in cash.
• The company repaid the remaining principal of its 5.25% Convertible Notes due June 1, 2024 (APHA 24 Notes) in cash upon maturity.

Sentiment

Score: 3

Explanation: The sentiment is negative due to a massive net loss driven by over $2 billion in impairment charges, a decline in adjusted EBITDA, and a Nasdaq delisting risk. While there's revenue growth in some segments and strategic acquisitions, the overall financial performance and significant write-downs overshadow these positives, indicating substantial underlying challenges and a high-risk investment profile.

Positives

• Total net revenue increased by 4% year-over-year, demonstrating overall top-line growth.
• Beverage net revenue increased by 19%, driven by new product launches and strategic acquisitions, positioning the company as the 4th largest craft brewer in the U.S.
• International cannabis net revenue increased by 19%, indicating strong growth and market leadership in global medical cannabis markets, particularly in Germany due to regulatory changes.
• Wellness net revenue increased by 9%, reflecting successful product range expansion and operational efficiencies.
• Adjusted gross margin for the cannabis segment improved to 40% from 36%, driven by increased international sales and a focus on higher-margin products.
• The company is actively pursuing cost reduction and cash generation through Project 420, having achieved $24.1 million in savings towards a $33 million target.
• Successful refinancing of the Aphria Diamond credit facility, repaying $48.17 million of prior debt.
• Maintained a strong working capital position of $408.3 million, indicating sufficient short-term liquidity.
• The company is leveraging AI across global operations to enhance efficiency, optimize processes, and reduce costs in cultivation.

Negatives

• Reported a significant net loss of $2.18 billion for fiscal year 2025, primarily due to substantial non-cash impairment charges.
• Incurred $2.096 billion in non-cash impairment charges on intangible assets and goodwill, reflecting a sustained decline in market capitalization and slower cannabis legalization progress.
• Cannabis net revenue decreased by 9%, with Canadian adult-use cannabis revenue declining by 16% due to price compression and a strategic shift of inventory to international markets.
• Adjusted EBITDA decreased by 9%, indicating a decline in operational profitability despite revenue growth in some segments.
• Cash used in operating activities increased to $94.6 million from $30.9 million, driven by additional working capital requirements in the beverage segment.
• The company's stock price experienced severe volatility, ranging from $0.42 to $2.03 during fiscal year 2025.
• The company received a Nasdaq non-compliance notice for its minimum bid price requirement ($1.00 per share) and has until September 21, 2025, to regain compliance.
• The company has a history of net losses and has not yet achieved profitability.
• The MedMen Convertible Note was written down by $21.7 million and subsequently disposed of in exchange for an option to acquire a 68% membership interest in SH Acquisition for $1.00 upon U.S. federal cannabis legalization, indicating a significant loss on this investment.

Risks

• Failure to achieve expected revenue or benefits from craft beer acquisitions.
• Difficulties integrating operations and realizing expected benefits from recent acquisitions.
• Dependence of cannabis business on regulatory approvals, licenses, ongoing compliance, and timely renewals.
• Evolving government regulation in the cannabis industry, including potential U.S. rescheduling and uncertainties in international legalization, could negatively impact business expansion.
• Intense competition, including from the illicit cannabis market, which could hurt business.
• Adverse changes or developments affecting production and processing facilities (e.g., disease, natural disaster, security breaches) could impact operations.
• Regulations constrain the ability to market and distribute products in Canada, potentially impairing brand differentiation.
• Uncertainty in evolving U.S. regulations for hemp-derived CBD and Delta-9 products, which could lead to enforcement actions or new restrictions.
• Changes in consumer preferences or public attitudes about alcohol could decrease demand for beverage products.
• Substantial competition in the beer and broader alcoholic beverage markets could impact business and financial results.
• Reliance on distributors for sustained growth and product distribution in the beverage segment.
• Exposure to significant liability and costs from litigation, arbitration, and demands, which could impact resources and reputation.
• Material adverse effects from the imposition of duties, tariffs, and other trade barriers.
• Additional impairments of goodwill, intangible, and other long-lived assets could materially impact financial results and stock price.
• Limited operating history and a history of net losses, with no assurance of future profitability.
• Risks related to international operations, including political, economic, and legal uncertainties, and difficulties in securing import/export permits.
• Inability to attract or retain key personnel, including those requiring security clearances.
• Increased labor costs, potential workforce organization, and labor-related disruptions.
• Significant interruptions in access to supply chains for key inputs could impair operations.
• Negative impacts from volatility in the political and economic environment, including sustained inflation and geopolitical conflicts (e.g., Ukraine-Russia, Israel-Iran).
• Risks associated with the transportation of products, including security breaches and rising costs.
• Products may be subject to recalls due to defects, contamination, or labeling issues, leading to significant costs and reputational damage.
• Exposure to product liability claims or regulatory action, exacerbated by potential adverse side effects of cannabis use.
• Unfavorable publicity or negative consumer/investor perception of the cannabis industry.
• Failure to comply with safety, health, and environmental regulations may expose the company to liability.
• Significant funding challenges and inability to secure adequate or reliable sources of funding for operations and expansion.
• Existing and future debt agreements may contain covenant restrictions limiting business operations.
• Inability to successfully establish and maintain effective internal controls over financial reporting.
• Fluctuations in foreign currency exchange rates could harm results of operations, particularly for Canadian dollar and Euro exposures.
• Exposure to greater than anticipated tax liabilities due to changing tax laws or interpretations.
• Inability to utilize net operating loss carryforwards, potentially resulting in higher tax liabilities.
• Failure to meet Nasdaq continued listing requirements could result in delisting.
• Uncertainty regarding the impact of a potential reverse stock split on investor confidence and share price.
• Volatility of stock and stockholder base may hinder beneficial corporate initiatives requiring shareholder approval.
• Terms of outstanding warrants may limit ability to raise additional equity capital or pursue acquisitions, causing dilution.
• Inability to raise funds necessary to settle conversions of convertible securities in cash or repurchase them upon a fundamental change.
• High risk and uncertainty in the planned cryptocurrency strategy due to market volatility and evolving regulatory landscape.
• Inability to adequately protect intellectual property, especially under U.S. federal law where cannabis remains illegal.
• Inability to realize full benefit of clinical trials or studies if ownership or exclusive rights to intellectual property are not secured on commercially reasonable terms.
• Inability to maintain adequate insurance coverage or commercially justifiable premiums, leading to uninsured liabilities.
• Significant company resources and management attention required for financial reporting obligations as a public company with dual listing.
• Heightened scrutiny as a cannabis company in Canada and the U.S. could adversely impact liquidity of shares.

Future Outlook

The company's strategy focuses on leveraging brands, infrastructure, and expertise to drive revenue growth, achieve industry-leading profitability, and build long-term shareholder value. This includes continued investment in data analytics and consumer insights, managing cost structure, and accelerating growth through an experienced leadership team. The company anticipates continued growth in its beverage portfolio, driven by new product development and brand awareness. In cannabis, it expects to enhance its global supply chain and increase cultivation footprint to support growing demand in Canadian and international markets. The company believes it is well-positioned to enter the U.S. cannabis market upon federal legalization, especially if cannabis is rescheduled to Schedule III. It also expects continued volatility in the wholesale cannabis market and will assess conditions quarterly. The company aims to optimize its capital structure and opportunistically purchase or exchange equity for convertible notes.

Management Comments

• Our CIO plays a pivotal role in assessing and managing material risks stemming from cybersecurity threats and is primarily responsible for the oversight of our overall cybersecurity risk management program, and coordinates with our external cybersecurity consultants.
• The Board receives quarterly and as needed updates on cybersecurity matters from the CIO and management on topics including threat landscape developments, incident response readiness, and program enhancements.
• Tilray's mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy, wellness and create memorable experiences.
• Our overall strategy is to leverage our brands, infrastructure, expertise and capabilities to drive revenue growth in the industries in which we compete, achieve industry-leading, profitability and build sustainable, long-term shareholder value.
• We are relentlessly focused on managing our cost structure and expenses in order to maintain our strong financial position.
• Our management team is complemented by experienced operators, cannabis industry experts, veteran beer and beverage industry specialists and leaders that are well-established in wellness foods, all of whom apply an innovative and consumer-centric approach to our businesses.
• We do not anticipate paying any cash dividends in the foreseeable future as we intend to utilize all available funds and any future earnings to support operations and to finance the growth and development of our business.
• We believe that existing cash, cash equivalents, marketable securities and cash generated by operations, together with access to external sources of funds, will be sufficient to meet our domestic and foreign capital needs for the short and long term outlook.
• As a result of delays in legalization across multiple markets, management continues to optimize our operating structure, headcount, as well as the elimination of other discretionary operational costs.
• We intend to use the net proceeds from the ATM Program to fund strategic and accretive acquisitions or investments in businesses and capital expenditures for acquired businesses, including potential acquisitions of assets in the U.S. and internationally in order to capitalize on expected regulatory advancements or expansion opportunities.
• We are committed to optimizing our capital structure and enhancing financial flexibility as we intend to continue to opportunistically purchase or exchange equity for the TLRY 27 Notes prior to their underlying maturity date in June 2027, subject to market conditions.
• We believe the recently enacted tariffs could impact input materials such as aluminum, hops, barley, malt and vape componentry which are partially imported but we intend to mitigate these impacts to the extent possible.

Industry Context

Tilray Brands operates at the nexus of the cannabis, beverage, wellness, and entertainment industries. In the U.S. beverage market, it is the 4th largest craft brewer, actively expanding its portfolio through acquisitions like Craft Acquisition I and II to build a diversified platform. In the Canadian cannabis market, Tilray maintains a leading position in terms of revenue, despite intense competition and price compression from approximately 1,000 Licensed Producers and the illicit market. Internationally, Tilray is a global leader in medical cannabis, particularly in Europe (Germany, Poland, UK, Ireland, Italy) and Australia, benefiting from evolving legalization efforts and its EU-GMP certified supply chain. The company is strategically positioning itself for potential U.S. federal cannabis legalization, leveraging its existing beverage distribution network. The broader industry faces challenges from evolving regulations, consumer preferences, and geopolitical factors, but Tilray aims to differentiate through brand equity, innovation, and cost optimization.

Comparison to Industry Standards

• Tilray Brands is the 4th largest craft brewer in the United States, according to the Brewers Association 2024 U.S. Craft Brewing Industry Figures Report, indicating a strong competitive position in the craft beverage sector compared to other craft brewers.
• The company continued to lead the Canadian cannabis market with the highest cannabis revenue in Canada, suggesting a dominant market share relative to other Canadian Licensed Producers.
• Tilray Medical is one of the largest suppliers of medical cannabis to patients, physicians, hospitals, pharmacies, researchers, and governments across five continents, demonstrating a significant global footprint compared to other medical cannabis providers.
• The company's EU-GMP certified production facilities in Portugal and Germany provide a competitive advantage in international medical cannabis markets, adhering to high quality standards comparable to pharmaceutical industry benchmarks.
• The acquisition of craft brands from Anheuser-Busch Companies, LLC and Molson Coors Beverage Company aligns with a broader industry trend of consolidation in the craft beverage sector, where larger entities acquire smaller craft brands to expand portfolios and distribution.
• The company's focus on SKU and geographic rationalization in its beverage segment, as part of Project 420, is a common strategy employed by consumer goods companies to optimize efficiency and profitability in competitive markets.
• The cannabis industry in Canada continues to experience price compression and a shift towards asset-light business models among competitors, which Tilray is navigating by focusing on higher-margin international sales and optimizing its supply chain.

Management Changes

Corporate Governance

Legal Proceedings

• Aphria Canadian Class Action: Settled on February 5, 2025, for CAD $30,000 (approx. US $21,000), with the company paying CAD $8,300 (approx. US $5,800) and the rest funded by D&O insurance and individual defendants. The settlement was approved on March 27, 2025, and became effective on April 28, 2025.
• Aphria Inc. Securities Litigation (New York, United States): Ongoing class action alleging misrepresentation of LATAM Assets' value. Class certified on April 12, 2024. The company continues to vigorously defend against claims.
• Dismissal of Martin Dionne suit v. HEXO Corporation and Sebastien St. Louis: Class action dismissed at certification stage in Quebec on January 23, 2023. Plaintiff's appeal was dismissed by the Quebec Court of Appeal on April 16, 2025. The company intends to pursue recovery of D&O policy retention amounts.
• Settlement and Dismissal of 420 Investments Ltd. Litigation: Lawsuit settled on May 11, 2025. Tilray paid a net amount of approximately $2,700, waived recovery on acquired claims, and assigned back a CAD $7,000 bridge loan plus interest and costs. All claims were dismissed with mutual releases.
• Fotmer Corporation S.A. v. Tilray Brands Inc. et al.: Arbitration awarded Fotmer $1,233 plus interest on August 8, 2023. Tilray has not paid, asserting equitable setoff due to a related court action in Berlin seeking $2,250 from Fotmer. Litigation is ongoing, with Tilray vigorously defending its position.
• Litigation accruals: Total estimated litigation expense accrual included in accrued liabilities as of May 31, 2025, was $12,431 (compared to $24,378 in 2024).

Related Party Transactions

• RIKI Ventures, LLC: The company had a 50% ownership and voting interest in this joint venture. There were no transactions in FY25, and the company dissolved its membership interest.
• Aphria Diamond Inc.: A 51% majority-owned subsidiary of Aphria, Inc. On September 16, 2024, Tilray acquired a promissory note of $23,792 from Double Diamond Holdings Ltd. (DDH), a joint venturer in Aphria Diamond, by issuing 13,217,588 shares of common stock to DDH.
• Aphria Diamond Inc.: On February 21, 2025, Aphria Diamond Inc. refinanced its existing term loan by entering into a new Credit Agreement for CAD $53,000,000, using CAD $48,171,221 to repay the prior credit facility.
• Holdings Note: The Holdings Note is a subordinated promissory note of $10,000,000 with the Borrower (American Beverage Crafts Group, Inc.) as debtor and Holdings (Tilray Brands, Inc.) as lender. Payments are restricted until after December 31, 2026, and subject to financial covenants and compliance with Section 7.12 (Restricted Activities).
• Executive Retention Agreements: On July 24, 2025, the Board approved fiscal year 2026 retention payments totaling $1,505,000 for five executives (Irwin Simon, Carl Merton, Denise Faltischek, Mitchell Gendel, Roger Savell), contingent on continued employment through August 31, 2026, with pro-rated repayment if employment terminates without 'Good Reason' or for 'Cause'.

Stakeholder Impact

• **Shareholders**: Significant net loss and impairment charges will negatively impact shareholder equity and potentially stock price. Nasdaq delisting risk poses a direct threat to liquidity and investment value. Dilution from ATM program and convertible note conversions is ongoing. The new clawback policy enhances accountability but could impact executive incentives.
• **Employees**: Restructuring costs indicate job terminations and severance payments. Retention payments for key executives aim to stabilize leadership. The company emphasizes a collaborative work environment and employee development.
• **Customers**: Strategic focus on brand building, innovation, and quality aims to enhance customer loyalty and satisfaction across cannabis, beverage, and wellness segments. SKU rationalization in beverages might affect product availability for some customers but aims for a more focused portfolio.
• **Suppliers**: Supply chain sustainability initiatives are being implemented, encouraging suppliers to improve environmental footprint. Geopolitical events and tariffs could impact input costs for suppliers and the company.
• **Creditors**: Debt refinancing and ongoing management of debt covenants are critical for maintaining financial stability and meeting obligations to creditors. The significant impairment charges could raise concerns about asset backing, though the company believes it has sufficient operating room with financial covenants.
• **Regulatory Authorities**: The company is subject to extensive and evolving regulations in multiple jurisdictions (Canada, U.S., Europe, Australia) across its diverse business segments. Compliance with these regulations is a continuous focus, and any non-compliance could lead to penalties or restrictions.

Next Steps

• Continue to focus on developing strong capabilities in data analytics and consumer insights to drive category management leadership and assess opportunities for new categories, products, and geographies.
• Relentlessly focus on managing cost structure and expenses to maintain a strong financial position.
• Continue to develop innovative cannabis products and form factors, optimizing cultivation and production facilities.
• Continue to invest in innovation to provide a differentiated portfolio of products, driven by research and insights.
• Drive growth in the beverage and hemp-based food businesses, focusing on consumer insights, marketing, and new product development.
• Expand into the emerging hemp-derived Delta-9 (HD-D9) product category.
• Be well-positioned to compete in the U.S. cannabis market in the event of federal legalization.
• Expand the availability of high-quality, consistent medical cannabis products globally, leveraging EU-GMP certified facilities and distribution networks.
• Maximize utilization of existing assets and investments for international growth plans.
• Optimize and drive efficiencies in global operations with a relentless focus on cost reduction and cash generation.
• Complete the synergy optimization plan under Project 420 in the third quarter of fiscal 2026.
• Actively monitor the closing bid price of common stock and evaluate available options to regain Nasdaq minimum bid price compliance by September 21, 2025.
• The Board of Directors will continue to consider whether and when to effect a reverse stock split.
• Continue to opportunistically purchase or exchange equity for the TLRY 27 Notes prior to their maturity date in June 2027.
• Open a separate deposit account for Cash Reserve Collateral and deposit $10,000,000 into it by August 8, 2025, maintaining this balance during the Minimum TTM EBITDA Testing Period.
• Consummate the Hemp Contribution and cause Hemp Entities to become Guarantors by September 23, 2025.
• Deliver updated intellectual property schedules, filings, stock certificates, and stock powers by September 8, 2025.
• Receive a cash contribution of not less than $10,000,000 by Holdings in exchange for common Equity Interests of the Borrower by December 31, 2025.
• Continue to vigorously defend against the Aphria Inc. Securities Litigation (New York, United States) claims.
• Pursue recovery of D&O policy retention amounts following the successful outcome of the HEXO Corp. class action appeal.

Key Dates

Recommendation

The company reported a staggering net loss of over $2.18 billion, primarily driven by massive non-cash impairment charges on goodwill and intangible assets, indicating a significant write-down of past acquisitions and a re-evaluation of asset values. This substantial loss, coupled with a decline in Adjusted EBITDA, signals underlying operational challenges despite some revenue growth in specific segments. The explicit Nasdaq delisting risk due to the low bid price adds immediate and severe uncertainty regarding the stock's liquidity and investor confidence. While strategic acquisitions and cost-saving initiatives are underway, the sheer magnitude of the impairments and the ongoing regulatory and competitive pressures in the cannabis industry present a highly unfavorable risk-reward profile for investors. The company's history of net losses and the need for potential future capital raises further compound the concerns. A seasoned investor would likely view these results as a strong signal to reduce or exit positions due to the significant financial deterioration and heightened risks.

Keywords

Cannabis, Beverage, Wellness, Distribution, SEC Filing, 10-K, Financial Results, Net Loss, Impairment, Goodwill, Intangible Assets, Revenue Growth, Adjusted EBITDA, Liquidity, Capital Structure, Acquisitions, Craft Beer, Medical Cannabis, Adult-Use Cannabis, Hemp-Derived Products, Nasdaq Listing, Risk Factors, Corporate Governance, Legal Proceedings, Convertible Notes, ATM Program, Project 420, Cybersecurity, ESG